{"id":"usual-dopaminergic-per-os-treatment","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dyspepsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the activation of dopamine receptors, which helps to improve symptoms of Parkinson's disease and other movement disorders. The exact mechanism is not fully understood, but it is thought to involve the stimulation of dopamine release and/or the inhibition of dopamine reuptake.","oneSentence":"Activates dopaminergic receptors to increase dopamine levels in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:45.034Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Prostate cancer"}]},"trialDetails":[{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":"Acute Aluminum Phosphide Poisoned Cases","enrollment":74},{"nctId":"NCT07400731","phase":"NA","title":"Short and Long-term Responses of PD Symptoms to Earstim","status":"NOT_YET_RECRUITING","sponsor":"Stoparkinson Healthcare Systems LLC","startDate":"2026-02","conditions":"PARKINSON DISEASE (Disorder)","enrollment":90},{"nctId":"NCT07045935","phase":"PHASE4","title":"Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-09-16","conditions":"Prolactinoma","enrollment":60},{"nctId":"NCT04332276","phase":"PHASE1, PHASE2","title":"Dopaminergic RestauratIon by IntraVEntriculaire Administration","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2020-09-18","conditions":"Parkinson Disease","enrollment":12},{"nctId":"NCT04553263","phase":"EARLY_PHASE1","title":"Relapse Prevention in Stimulant Use Disorder","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-06-11","conditions":"Stimulant Use, Relapse, Cognitive Function","enrollment":""},{"nctId":"NCT01039090","phase":"PHASE3","title":"Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2009-02","conditions":"Parkinsons's Disease","enrollment":21},{"nctId":"NCT05016076","phase":"NA","title":"Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial","status":"WITHDRAWN","sponsor":"YingHsuanTai","startDate":"2022-05","conditions":"Obesity, Bariatric Surgery Candidate, Tracheal Intubation Morbidity","enrollment":""},{"nctId":"NCT04107480","phase":"PHASE4","title":"PRolaCT - Three Prolactinoma RCTs","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2019-06-21","conditions":"Prolactinoma, Prolactin-Producing Pituitary Tumor","enrollment":880},{"nctId":"NCT01044992","phase":"NA","title":"Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2002-05","conditions":"Multisystemic Atrophy","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Usual dopaminergic per os treatment","genericName":"Usual dopaminergic per os treatment","companyName":"Rennes University Hospital","companyId":"rennes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Activates dopaminergic receptors to increase dopamine levels in the brain. Used for Parkinson's disease, Prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}